<DOC>
	<DOCNO>NCT02908217</DOCNO>
	<brief_summary>Patients treat infusion Tocilizumab ( TCZ ) placebo 5 month . Clinical evaluation perform use PMR-AS . The PMR-AS compute sum 5 variable multiply 0.1 weighting purpose : PMR-AS ( activity scale = AS ) = C reactive protein ( CRP ) ( mg/dl ) + patient scale ( VASp ) ( 0-10 scale ) + physician scale ( VASph ) ( 0-10 scale ) + morning stiffness ( MST ) [ min ] Ã—0.1 ) + elevation upper limb ( EUL ) ( 0-3 scale ) . All patient include treat glucocorticoid ( GC ) .GC reduce visit end study , depend response treatment PMR-AS .</brief_summary>
	<brief_title>Safety Efficacy tocilizuMAb Versus Placebo Polymyalgia rHeumatica With glucocORticoid dEpendence SEMAPHORE</brief_title>
	<detailed_description />
	<mesh_term>Polymyalgia Rheumatica</mesh_term>
	<mesh_term>Giant Cell Arteritis</mesh_term>
	<mesh_term>Glucocorticoids</mesh_term>
	<criteria>Age old 50 year Fulfilled Chuang criterion And currently : PMRAS &gt; 10 Absence sign symptom musculoskeletal connective tissue condition Able give inform consent Concomitant treatment methotrexate hydroxychloroquine permit stable dose since 3 month . Clinical symptom giant cell arteritis Uncontrolled dyslipidemia , high blood pressure cardiovascular disease History major organ haematopoietic stem cell/marrow transplant Clinical evidence significant unstable uncontrolled acute chronic disease due PMR Planned surgical procedure within 12 month randomization . History malignant neoplasm within last 5 year . Current active infection Patient elevate ALT AST &gt; 5 ULN</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Polymyalgia Rheumatica</keyword>
	<keyword>Tocilizumab</keyword>
	<keyword>Glucocorticoid</keyword>
</DOC>